Pharmaceutical Technology E-Alert:
Having trouble viewing this e-mail? Click here.
  Pharmaceutical Technology Europe E-Alert
 
5 October 2012

IN THIS ISSUE
EMA biosimilars guidance
Merck spin-off
Biopharma trends
US innovation
Twitter

 
EMA Aims to Facilitate Biosimilars Development
The European Medicines Agency has updated its guidance on biosmilar medicines, with the aim of helping companies to avoid unnecessary repetition of clinical trials. More...
 
Merck Serono Launches New Spin-off Company
Merck Serono has launched a new spin-off company, Asceneuron, which will focus on developing therapies for treating Alzheimer’s disease and Tau protein-related pathologies. More...
 
Biopharma Industry Set to See New Technologies and New Therapies
A new report has forecast that the global biopharmaceutical market will be worth more than $320 billion by 2020, up from just $138 billion in 2011. More...
 
Report Identifies Hurdles to Innovation in the US
A report has identified two major areas related to drug discovery and development in the US that should be addressed to advance the country’s innovation. More...
 
Get the Latest Updates on Twitter
We regularly tweet the latest news and rumours hitting the web about the pharmaceutical industry. Follow us to keep up to date. More...
Key Topics:

Latest blog posts
ISPE Annual Meetings Seeks to Foster Global Change
How to Reach First-in-Man Studies Successfully
Is FDA Putting your Company's Confidential Data at Risk?
More blog posts

Latest articles
Joint Regulatory Conferences: The Ultimate Connection
Formulation Development Forum: Hydrogels for Long-Sustained Release
Campaign Mounts to Curb Counterfeit Drugs
More articles

Upcoming events
2012 AAPS (14–18 October | USA)
ICH Q 9 Training Course (24–25 October | Austria)
Virus and TSE Safety Made Simple (30–31 October | Germany)
More events

Products/Service Profiles
Agilent

Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn more at www.agilent.com/lifesciences/realizepharma

 
Agilent

Agilent ICP-MS/ICP-OES
Reliable solutions for regulated pharmaceutical laboratories

Complying with new elemental impurity limits as defined by draft USP methods <232>/<233> could pose a significant challenge. You need to choose qualified hardware and software, ensure verification, and maintain electronic records. But there is a simple answer – Request a free copy of our primer on Elemental Impurity Analysis to learn more

 
BASF SE

Ludiflash® is a combined filler, binder and disintegrant that is used to create fast-dissolving, fast-acting formulations with an exceptionally smooth and creamy mouthfeel. Read more

 
Intertek

Pharma and Biopharma Outsourcing Solutions from Intertek
Intertek‘s expert pharmaceutical analysis, auditing and regulatory services are helping clients to save costs. Successful innovative, tailored programmes for biologics and pharmaceuticals can be applied to product / clinical development and manufacturing. ICSE, Stand 10E89. Read more


Event Profile
Perkin Elmer

3 Live Webinars coming soon.
Supply chain security - how best to use the most important tool in supply chain protection
Infrared spectroscopy is the most economical way to screen against many of the risks that exist today in your supply chain of raw materials – counterfeit, contaminated, adulterated, diluted, substituted, false claims of purity/source etc.
Read more


Event Profile
Special Supplement

Solubilization Solutions
In a special PharmTech issue, current and emerging bioavailability challenges are examined. Articles address solutions and approaches for solubilization as related to solid dispersions by hot-melt extrusion, lipophilic excipients, lipid-based formulations, spray drying, and more.
Read more

 
Survey
The European Generic Medicines Agency has recently claimed that the potential fees to be charged by the European Medicines Agency for pharmacovigilance activities are unjustifiably high. Do you agree?
 
Yes 89%
 
 
No 8%
     
 
The wording of the fees is not clear 3%

This week we would like to know...

Do you think the growing number of anticounterfeiting technologies technologies, coupled with increased focus from regulators, have had a positive impact on reducing the number of counterfeit pharmaceuticals in the legal supply chain?

Click here to vote

Contact Us
Click here to contact editorial.

Click here to contact sales.